These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 21118740)

  • 21. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A; Pastores GM; Tylki-Szymanska A; Hughes DA; Elstein D; Mardach R; Eng C; Smith L; Heisel-Kurth M; Charrow J; Harmatz P; Fernhoff P; Rhead W; Longo N; Giraldo P; Ruiz JA; Zahrieh D; Crombez E; Grabowski GA
    Am J Hematol; 2013 Mar; 88(3):172-8. PubMed ID: 23339116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
    Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
    Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy with imiglucerase in Taiwanese patients with type I Gaucher disease.
    Hsu CC; Chien YH; Lai MY; Hwu WL
    J Formos Med Assoc; 2002 Sep; 101(9):627-31. PubMed ID: 12645190
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transformation in pretreatment manifestations of Gaucher disease type 1 during two decades of alglucerase/imiglucerase enzyme replacement therapy in the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Mistry PK; Batista JL; Andersson HC; Balwani M; Burrow TA; Charrow J; Kaplan P; Khan A; Kishnani PS; Kolodny EH; Rosenbloom B; Scott CR; Weinreb N
    Am J Hematol; 2017 Sep; 92(9):929-939. PubMed ID: 28569047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H; Gonzalez DE; Barton NW; Zimran A; Kabra M; Lukina EA; Giraldo P; Kisinovsky I; Bavdekar A; Ben Dridi MF; Gupta N; Kishnani PS; Sureshkumar EK; Wang N; Crombez E; Bhirangi K; Mehta A
    Am J Hematol; 2013 Mar; 88(3):179-84. PubMed ID: 23400823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment.
    Weinreb NJ; Camelo JS; Charrow J; McClain MR; Mistry P; Belmatoug N;
    Mol Genet Metab; 2021 Feb; 132(2):100-111. PubMed ID: 33485799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of pregnancy in Gaucher disease.
    Granovsky-Grisaru S; Belmatoug N; vom Dahl S; Mengel E; Morris E; Zimran A
    Eur J Obstet Gynecol Reprod Biol; 2011 May; 156(1):3-8. PubMed ID: 21269752
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thromboelastography Before Epidural Placement in a Thrombocytopenic Parturient With Gaucher Disease Treated With Imiglucerase: A Case Report.
    Tharp WG; Farhang B
    A A Pract; 2018 Jul; 11(1):16-18. PubMed ID: 29634566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P; Irún P; Alfonso P; Dalmau J; Fernández-Galán MA; Figueredo A; Hernández-Rivas JM; Julia A; Luño E; Marín-Jimenez F; Martín-Nuñez G; Montserrat JL; de la Serna J; Vidaller A; Villalón L; Pocovi M
    Blood Cells Mol Dis; 2011 Jan; 46(1):115-8. PubMed ID: 20934891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of pregnancies in women receiving velaglucerase alfa for Gaucher disease.
    Elstein D; Hughes D; Goker-Alpan O; Stivel M; Baris HN; Cohen IJ; Granovsky-Grisaru S; Samueloff A; Mehta A; Zimran A
    J Obstet Gynaecol Res; 2014 Apr; 40(4):968-75. PubMed ID: 24612151
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement of life quality measured by Lansky Score after enzymatic replacement therapy in children with Gaucher disease type 1.
    Cerón-Rodríguez M; Barajas-Colón E; Ramírez-Devars L; Gutiérrez-Camacho C; Salgado-Loza JL
    Mol Genet Genomic Med; 2018 Jan; 6(1):27-34. PubMed ID: 29471591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. First experience with enzyme replacement therapy during pregnancy and lactation in Pompe disease.
    de Vries JM; Brugma JD; Ozkan L; Steegers EA; Reuser AJ; van Doorn PA; van der Ploeg AT
    Mol Genet Metab; 2011 Dec; 104(4):552-5. PubMed ID: 21967859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The long-term international safety experience of imiglucerase therapy for Gaucher disease.
    Starzyk K; Richards S; Yee J; Smith SE; Kingma W
    Mol Genet Metab; 2007 Feb; 90(2):157-63. PubMed ID: 17079176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 multi-center, open-label, switch-over trial to evaluate the safety and efficacy of Abcertin® in patients with type 1 Gaucher disease.
    Choi JH; Lee BH; Ko JM; Sohn YB; Lee JS; Kim GH; Heo SH; Park JY; Kim YM; Kim JH; Yoo HW
    J Korean Med Sci; 2015 Apr; 30(4):378-84. PubMed ID: 25829804
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imiglucerase and its use for the treatment of Gaucher's disease.
    Weinreb NJ
    Expert Opin Pharmacother; 2008 Aug; 9(11):1987-2000. PubMed ID: 18627336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic changes of lipid profile in Romanian patients with Gaucher disease type 1 under enzyme replacement therapy: a prospective study.
    Zimmermann A; Grigorescu-Sido P; Rossmann H; Lackner KJ; Drugan C; Al Khzouz C; Bucerzan S; Naşcu I; Zimmermann T; Leucuţa D; Weber MM
    J Inherit Metab Dis; 2013 May; 36(3):555-63. PubMed ID: 22976766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D; Patterson MA
    J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease.
    Pastores GM
    BioDrugs; 2010 Feb; 24(1):41-7. PubMed ID: 20055531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.